A Complete Retreat: “Protected Classes” Stay Protected In US Medicare
CMS has abandoned its plan to give private plans more leverage in the “protected” drug classes in Part D. It will probably be a long time before anyone tries to change the protected classes again.
You may also be interested in...
Healthy Adult Opportunity initiative (don’t call it block grants) adopts some, but not all, of Medicare Part D’s protected classes, allowing states to exclude some drugs from coverage in the expansion Medicaid population to drive additional savings.
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
Legislation clears committee with no major changes. However, the number of Republicans opposing the bill due to concerns over price inflation rebates portend difficulties ahead for a floor vote.